Actinogen Medical Ltd (acw) Logo

Actinogen Medical Ltd (ACW)

___:___ · Healthcare

ACW Chart


ACW's Principal Activity is the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +420.51%
vs ASX 200 (1yr) +402.62%


Market Capitalisation
ASX Rank 768 of 2,316
Sector Rank 62 of 198

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies ONT / CYC / KZA
EPS -$0.003
DPS $0.00
NTA per share $0.01

Broker Consensus

ACW is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Actinogen Medical Limited (ACW, formerly Actinogen Limited) is an ASX-listed biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. It focusses on the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases within Australia.

Incorporation Details

Incorporated Actinogen Limited was incorporated on 26/03/1999 in Western Australia.

Corporate Details

Head Office Sydney NSW 2000
Registry Automic Group
Auditor Ernst & Young
Date Listed 16 Oct 2007

Upcoming Calendar (Forecasted)

Date Event
25/10/2021 Report (Annual)
23/02/2022 Report (Interim)
29/08/2022 Report (Prelim)
29/08/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Steven Gourlay Chief Executive Officer,Managing Director Mar 2021 Director Bio icon

Dr Steven Gourlay

Chief Executive Officer,Managing Director

Dr Gourlay has more than 30 years of experience in the development of novel therapeutics. Formerly the founding Chief Medical Officer (CMO) at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, Phase 2 and 3 clinical trial programs for four small molecules in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay's roadshow presentations, supported a NASDAQ IPO of Principia Biopharma Inc. in 2018 - subsequently followed by an acquisition of by Sanofi in 2020. Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, the Australian specialist life sciences and healthcare venture capital firm, where he was involved in the development and exit of multiple clinical stage therapeutic companies including Elastagen, Spinifex and Peplin. Before GBS, and after a postdoc in clinical pharmacology at the University of California San Francisco, he held positions of increasing responsibility at Genentech, Inc. in the areas of pharmacoepidemiology and early clinical development. Dr Gourlay has drug regulatory experience with the US Food and Drug Administration (FDA), European Medicines Agency (EMA) at many levels, including filing more than 10 Investigational New Drug (IND) applications, achieving several orphan drug status approvals for his Company's product(s), and completing several biologics license applications. Dr Gourlay has been acting as a consultant CMO to Actinogen since December 2020.

Dr Geoffrey E.D Brooke Non-Executive Chairman,Non-Executive Director Feb 2021 Director Bio icon

Dr Geoffrey E.D Brooke

Non-Executive Chairman,Non-Executive Director

Dr Brooke is a healthcare industry and venture capital veteran with over 30 years' international experience as the founder, lead investor and/or Chairman/Director of numerous healthcare companies. He was the Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures. There, Dr Brooke was responsible for GBS's healthcare venture activity in the region. Dr Brooke was also responsible for numerous investments and exits via NASDAQ and ASX public listings and trade sales, as well as being lead investor in numerous investments syndicated in multiple rounds with premier US venture firms. Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc., with investors including the venture capital arm of global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Dr Brooke now acts as a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies.

Mr Malcolm John McComas Non-Executive Director Apr 2019 Director Bio icon

Mr Malcolm John McComas

Non-Executive Director

Mr McComas has over 25 years of experience in the financial services industry with experience in corporate finance, mergers and acquisitions, debt and equity funding transactions across multiple industry sectors. He held senior leadership roles with Grant Samuel, County NatWest (now Citigroup) and Morgan Grenfell (now Deutsche Bank) in Australia and the UK. Prior to this Mr McComas was a lawyer at Herbert Geer specialising in tax. Mr McComas is an experienced company director and currently services number of listed entities, and also has not-for-profit involvement as a director of the Australasian Leukemia and Lymphoma Group.

Dr George Morstyn Non-Executive Director Dec 2017 Director Bio icon

Dr George Morstyn

Non-Executive Director

Dr Morstyn has more than 25 years; experience in the biotechnology industry including as Senior Vice President of Development and Chief Medical Officer at Amgen Inc. Dr Morstyn had responsibility globally for drug development in all therapeutic areas including neuroscience at Amgen Inc. and was a member of the Operating Committee. Many new products were approved and launched during Dr Morstyn's tenure. Prior to joining Amgen Inc. Dr Morstyn has been a Non-Executive Director of various for-profit and not-for-profit companies, including many biotechnology companies. He is currently on the Board of the Cooperative Research Centre for Cancer Therapeutics, Symbio (Tokyo) and Biomedical Research Victoria.

Mr Peter Webse Company Secretary N/A

Director Transactions

ACW directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
17/11/20 Malcolm McComas Issued 100,000 $0.022 $2,200 Rights issue
17/11/20 George Morstyn Issued 40,000 $0.022 $880 Rights issue
17/11/20 John (Bill) Ketelbey Issued 1,862,182 $0.022 $40,968 Rights issue
17/11/20 John (Bill) Ketelbey Issued 128,579 $0.022 $2,828 Rights issue
17/11/20 Geoffrey Brooke Issued 265,000 $0.022 $5,830 Rights issue
31/01/20 John (Bill) Ketelbey Cancelled 3,000,000 $0.035 $105,000 Cancellation of securities
22/11/19 John (Bill) Ketelbey Transfer 9,000,000 $0.05 $450,000 As advised by the company
22/11/19 John (Bill) Ketelbey Transfer 9,000,000 $0.05 $450,000 As advised by the company
12/04/19 Malcolm McComas Issued 3,000,000 $0.052 $156,000 Issue of options
13/12/18 Geoffrey Brooke Issued 4,900,000 $0.048 $235,200 Issue of options
13/12/18 John (Bill) Ketelbey Issued 11,700,000 $0.048 $561,600 Issue of options

Director Interests

The current holdings of ACW directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Steven Gourlay 24/03/2021 N/A 63,362,300 N/A N/A
Geoffrey Brooke 17/11/2020 0 1,590,000 9,900,000 N/A
Malcolm McComas 17/11/2020 N/A 600,000 3,000,000 N/A
George Morstyn 17/11/2020 N/A 240,000 3,000,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Oct 5, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
HSBC Custody Nominees (Australia) Limited 227,303,623 20.36%
Edinburgh Technology Fund Limited 48,147,864 4.31%
Surfit Capital Pty Ltd 30,000,000 2.69%
Tisia Nominees Pty Ltd (Henderson Family A/C) 27,867,184 2.50%
Mrs Sarah Cameron 25,916,573 2.32%
Brazil Farming Pty Ltd 15,000,000 1.34%
Citicorp Nominees Pty Ltd 10,604,474 0.95%
Mr Steven Veronese 10,008,001 0.90%
Oaktone Nominees Pty Ltd (Grist Investment A/C) 10,000,000 0.90%
Mrs Gillian Karen Nes & Mrs Ronald Nes (Giro S/F A/C) 9,950,000 0.89%
Kaleidoscope Holdings Pty Ltd (Kaleidoscope Super A/C) 9,000,000 0.81%
Griffin & Grace Investments Pty Ltd (Griffin & Grace Inv S/F A/C) 8,800,000 0.79%
Mr Peter James Nixon 8,400,000 0.75%
Alua Capital Pty Ltd 8,000,000 0.72%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd Drp 7,738,901 0.69%
BNP Parabis Nominees Pty Ltd (Bnpp Nyb Clearing Acc Drp) 7,560,729 0.68%
Bannaby Investments Pty Ltd (Super Fund A/C) 7,500,000 0.67%
Webinvest Pty Ltd (Olsb Unit A/C) 7,000,000 0.63%
Romfal Sifat Pty Ltd (The Fizmail Family A/C) 7,000,000 0.63%
Paranji Super Fund Pty Ltd (Paranji Superfund A/C) 6,500,000 0.58%

Shareholder Distribution

As reported in the most recent Annual Report.

The most recent Annual Report didn't contain Shareholder Distribution data.

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
BVF Partners L.P 10/02/2021 239,927,273 14.88

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.022 30 June
2019 $0.01 28 June
2018 $0.048 29 June
2017 $0.061 28 June
2016 $0.072 28 June
2015 $0.072 30 June
2014 $0.011 30 June
Page Icon
ACW Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.